中东呼吸综合征冠状病毒医学应对措施的研发
Development of Medical Countermeasures to Middle East Respiratory Syndrome Coronavirus.
作者信息
Uyeki Timothy M, Erlandson Karl J, Korch George, O'Hara Michael, Wathen Michael, Hu-Primmer Jean, Hojvat Sally, Stemmy Erik J, Donabedian Armen
出版信息
Emerg Infect Dis. 2016 Jul;22(7). doi: 10.3201/eid2207.160022. Epub 2016 Jul 15.
Abstract
Preclinical development of and research on potential Middle East respiratory syndrome coronavirus (MERS-CoV) medical countermeasures remain preliminary; advancements are needed before most countermeasures are ready to be tested in human clinical trials. Research priorities include standardization of animal models and virus stocks for studying disease pathogenesis and efficacy of medical countermeasures; development of MERS-CoV diagnostics; improved access to nonhuman primates to support preclinical research; studies to better understand and control MERS-CoV disease, including vaccination studies in camels; and development of a standardized clinical trial protocol. Partnering with clinical trial networks in affected countries to evaluate safety and efficacy of investigational therapeutics will strengthen efforts to identify successful medical countermeasures.
摘要
中东呼吸综合征冠状病毒（MERS-CoV）潜在医学应对措施的临床前开发和研究仍处于初步阶段；在大多数应对措施准备好进行人体临床试验之前，还需要取得进展。研究重点包括用于研究疾病发病机制和医学应对措施疗效的动物模型和病毒株的标准化；MERS-CoV诊断方法的开发；改善获取非人类灵长类动物以支持临床前研究；开展研究以更好地理解和控制MERS-CoV疾病，包括在骆驼中进行疫苗接种研究；以及制定标准化的临床试验方案。与受影响国家的临床试验网络合作，评估研究性治疗方法的安全性和有效性，将加强识别成功医学应对措施的工作。
相似文献
1
Development of Medical Countermeasures to Middle East Respiratory Syndrome Coronavirus.
Emerg Infect Dis. 2016 Jul;22(7). doi: 10.3201/eid2207.160022. Epub 2016 Jul 15.
2
Toward Developing a Preventive MERS-CoV Vaccine-Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14-15, 2015.
Emerg Infect Dis. 2016 Aug;22(8). doi: 10.3201/eid2208.160229.
3
Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease.
J Virol. 2015 Oct 7;90(1):57-67. doi: 10.1128/JVI.02009-15. Print 2016 Jan 1.
4
Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches.
Curr Opin Virol. 2017 Apr;23:49-58. doi: 10.1016/j.coviro.2017.03.007. Epub 2017 Apr 13.
5
MERS-CoV‒Specific T-Cell Responses in Camels after Single MVA-MERS-S Vaccination.
Emerg Infect Dis. 2023 Jun;29(6):1236-1239. doi: 10.3201/eid2906.230128.
6
Middle East Respiratory Syndrome Coronavirus Antibodies in Bactrian and Hybrid Camels from Dubai.
mSphere. 2020 Jan 22;5(1):e00898-19. doi: 10.1128/mSphere.00898-19.
7
Middle East respiratory syndrome vaccines.
Int J Infect Dis. 2016 Jun;47:23-8. doi: 10.1016/j.ijid.2016.04.008. Epub 2016 Apr 7.
8
Vaccines against Middle East respiratory syndrome coronavirus for humans and camels.
Rev Med Virol. 2017 Mar;27(2). doi: 10.1002/rmv.1917. Epub 2016 Oct 27.
9
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Dromedary Camels in Africa and Middle East.
Viruses. 2019 Aug 5;11(8):717. doi: 10.3390/v11080717.
10
Blocking transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) in llamas by vaccination with a recombinant spike protein.
Emerg Microbes Infect. 2019;8(1):1593-1603. doi: 10.1080/22221751.2019.1685912.
引用本文的文献
1
Research prioritisation in preparedness for and response to outbreaks of high-consequence pathogens: a scoping review.
BMC Med. 2025 Mar 10;23(1):147. doi: 10.1186/s12916-025-03973-8.
2
Drug Repurposing: Insights into Current Advances and Future Applications.
Curr Med Chem. 2025;32(3):468-510. doi: 10.2174/0109298673266470231023110841.
3
(+)-Usnic acid and its salts, inhibitors of SARS-CoV-2, identified by using in silico methods and in vitro assay.
Sci Rep. 2022 Jul 30;12(1):13118. doi: 10.1038/s41598-022-17506-3.
4
Systems Biology Approaches for Therapeutics Development Against COVID-19.
Front Cell Infect Microbiol. 2020 Oct 28;10:560240. doi: 10.3389/fcimb.2020.560240. eCollection 2020.
5
Utilizing drug repurposing against COVID-19 - Efficacy, limitations, and challenges.
Life Sci. 2020 Oct 15;259:118275. doi: 10.1016/j.lfs.2020.118275. Epub 2020 Aug 17.
6
A novel luciferase immunosorbent assay performs better than a commercial enzyme-linked immunosorbent assay to detect MERS-CoV specific IgG in humans and animals.
Biosaf Health. 2019 Dec;1(3):134-143. doi: 10.1016/j.bsheal.2019.12.006. Epub 2019 Dec 20.
7
Nanomaterials and Nanotechnology-Associated Innovations against Viral Infections with a Focus on Coronaviruses.
Nanomaterials (Basel). 2020 May 31;10(6):1072. doi: 10.3390/nano10061072.
8
Functional Carbon Quantum Dots as Medical Countermeasures to Human Coronavirus.
ACS Appl Mater Interfaces. 2019 Nov 20;11(46):42964-42974. doi: 10.1021/acsami.9b15032. Epub 2019 Nov 6.
9
Development of a recombinant replication-deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in mice.
PLoS One. 2019 Oct 7;14(10):e0223684. doi: 10.1371/journal.pone.0223684. eCollection 2019.
10
Core Minimal Datasets to Advance Clinical Research for Priority Epidemic Diseases.
Clin Infect Dis. 2020 Feb 3;70(4):696-697. doi: 10.1093/cid/ciz760.
本文引用的文献
1
Time Course of MERS-CoV Infection and Immunity in Dromedary Camels.
Emerg Infect Dis. 2016 Dec;22(12):2171-2173. doi: 10.3201/eid2212.160382. Epub 2016 Dec 15.
2
Experimental Infection and Response to Rechallenge of Alpacas with Middle East Respiratory Syndrome Coronavirus.
Emerg Infect Dis. 2016 Jun;22(6):1071-4. doi: 10.3201/eid2206.160007. Epub 2016 Jun 15.
3
MERS-CoV Infection of Alpaca in a Region Where MERS-CoV is Endemic.
Emerg Infect Dis. 2016 Jun;22(6):1129-31. doi: 10.3201/eid2206.152113. Epub 2016 Jun 15.
4
Infection, Replication, and Transmission of Middle East Respiratory Syndrome Coronavirus in Alpacas.
Emerg Infect Dis. 2016 Jun;22(6):1031-7. doi: 10.3201/2206.160192. Epub 2016 Jun 15.
5
Prophylaxis With a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)-Specific Human Monoclonal Antibody Protects Rabbits From MERS-CoV Infection.
J Infect Dis. 2016 May 15;213(10):1557-61. doi: 10.1093/infdis/jiw080. Epub 2016 Mar 3.
6
Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo.
Sci Transl Med. 2016 Feb 17;8(326):326ra21. doi: 10.1126/scitranslmed.aaf1061.
7
A Comparative Review of Animal Models of Middle East Respiratory Syndrome Coronavirus Infection.
Vet Pathol. 2016 May;53(3):521-31. doi: 10.1177/0300985815620845. Epub 2016 Feb 11.
8
Coronaviruses - drug discovery and therapeutic options.
Nat Rev Drug Discov. 2016 May;15(5):327-47. doi: 10.1038/nrd.2015.37. Epub 2016 Feb 12.
9
Clinicopathologic, Immunohistochemical, and Ultrastructural Findings of a Fatal Case of Middle East Respiratory Syndrome Coronavirus Infection in the United Arab Emirates, April 2014.
Am J Pathol. 2016 Mar;186(3):652-8. doi: 10.1016/j.ajpath.2015.10.024. Epub 2016 Feb 5.
10
3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012.
Virology. 2016 Mar;490:49-58. doi: 10.1016/j.virol.2016.01.004. Epub 2016 Jan 30.
Zotero 插件